Skip to main content
. 2009 Apr;133(4):421–438. doi: 10.1085/jgp.200810097

TABLE II.

Comparison of blocker impact on RIV for all HBE monolayers

Drug order Basal Forskolin GlyH-101 Forskolin+GlyH-101 Forskolin+Glibenclamide GlyH-101+Forskolin Glibenclamide+Forskolin
wtHBE 1.06 ± 0.01 1.06 ± 0.02 0.97 ± 0.01 0.83 ± 0.03 1.39 ± 0.14 0.89 ± 0.01 1.50 ± 0.03
GP adjusteda 1.17 ± 0.06 0.90 ± 0.05 0.66 ± 0.03

Order of agonist or blocker represents experimental additions. Each measurement represents an n ≥ 6.

a

Values calculated with correction for paracellular conductance.